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Association of quality of life
measures with afamelanotide
treatment in patients with
erythropoietic protoporphyria and
x-linked protoporphyria: A
retrospective cohort study

LETTER

Of the 20 patients with EPP and 2 with XLP who
received at least 1 afamelanotide dose, 21 (95.5%)
returned for a second dose and 17 (77.3%) returned
for a third dose within 1 year. A total of 77 EPP-QoL
questionnaires were analyzed. Dropouts were due to
missing or incomplete data, insurance reimbursement restrictions, or transfer to a different treatment
center. No patients discontinued drug due to side
effects or lack of efficacy. Waning efficacy between
doses (around 6 weeks) was reported in 11 (50%)
patients and persistently low tolerance to sunlight
(#1 hour) was described in 9 (40.9%) patients. EPPQoL significantly increased from baseline at all
timepoints (P \ .001) and results were not significantly different from the phase III randomized
placebo-controlled trial (Table I; P [ .1).2 Each
consecutive implant showed incremental improvement in EPP-QoL from baseline, with the first implant
showing the greatest change (137.2, 148.7, 153.6;
P \ .001). Subgroup analysis revealed a smaller
magnitude of improvement in those who experienced waning efficacy and persistently low tolerance
to sunlight (Table II). A significantly smaller degree
of EPP-QoL improvement was found in those who
were unable to tolerate over 1 hour of sunlight with
the first afamelanotide treatment (114.6 vs 155.3,
P \.001).
The EPP-QoL is the only QoL tool designed for
EPP and, despite partial validation, captured treatment response was better than the Dermatology Life
Quality Index in previous studies.2 Although nonvalidated tools cannot be relied upon, consideration
of the results is reasonable, since instrument validation is difficult for rare conditions such as EPP/XLP.3
However, validated outcome measures are being
developed.4

To the Editor: Erythropoietic protoporphyria (EPP)
and X-linked protoporphyria (XLP; EPP/XLP) are
uncommon inherited heme-synthesis disorders characterized by painful cutaneous photosensitivity reactions from light-induced activation of accumulated
protoporphyrin IX. Afamelanotide is the only medication with clinical effectiveness, favorable safety
profile, and significantly improved EPP-specific
quality of life (QoL; EPP-QoL).1,2 However, full
year-round symptom control is challenging in certain
subgroups because of restrictions imposed by insurance companies on dose and frequency. We investigated how therapeutic responses to afamelanotide
affect QoL in patients with EPP/XLP in a real-word,
non-clinical trial setting.
This single-center retrospective study included
all patients with EPP/XLP who were treated with
afamelanotide between 2020 and 2021. QoL assessments were from the disease-specific EPP-QoL
questionnaire completed at each visit before implantation (Supplementary Fig 1, available via
Mendeley at https://doi.org/10.17632/7tcss39myf.
2). Paired t tests were used to compare mean score
changes from EPP-QoL questionnaires and EPPQoL outcomes in documented treatment response
subgroups. Two-sample t test was used to compare
EPP-QoL outcomes to those of a phase III randomized placebo-controlled trial.2 A larger positive
change in EPP-QoL score from baseline indicates
improvement in disease-specific QoL.

Table I. Changes in erythropoietic protoporphyria quality of life scores following each afamelanotide implant
in patients with erythropoietic protoporphyria and x-linked protoporphyria compared to baseline and a multicenter phase III randomized placebo-controlled trial2
Multi-center phase III RCT2 Paired t testy 2-sample t testz

Single-center
Timepoint

DEPP QoL score No. of completed DEPP QoL score
No. of
(Mean 6 SD) questionnaires (n) (Mean 6 SD) patients (n)

Baseline (Visit 1)
19.9 6 11.8
Implant 1 (Visit 2 minus 1)
137.2 6 27.5
Implants 1 1 2 (Visit 3 minus 1)
148.7 6 26.9
Implants 1 1 2 1 3 (Visit 4 minus 1) 153.6 6 18.0

20
18
13
10

26.6
117.4
123.2
124.5

6
6
6
6

19.9
5.9
6.5
9.2

47
47
46
46

P value

P value

—
\.001*
\.001*
\.001*

.166
.354
.895
.796

EPP, Erythropoietic protoporphyria; QoL, quality of life; RCT, randomized controlled trial.
*Statistically significant, P \ .05.
y
P values for the single-center comparison of mean score change at each timepoint to baseline score were determined by the paired t test.
z
In the comparison of single-center to multi-center phase III randomized placebo-controlled trial, P values were determined by the 2-sample
t test.2
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Table II. Changes in erythropoietic protoporphyria quality of life scores following each afamelanotide
implant in treatment response subgroups of patients with erythropoietic protoporphyria and x-linked
protoporphyria
Duration of full therapeutic response
\2 Months

$2 Months

Paired t test

Timepoint

DEPP QoL score
(Mean 6 SD)

No. of completed
questionnaires (n)

DEPP QoL score
(Mean 6 SD)

No. of completed
questionnaires (n)

P value

Implant 1 (Visit 2 minus 1)
Implants 1 1 2 (Visit 3 minus 1)
Implants 1 1 2 1 3 (Visit 4 minus 1)

129.4 6 29.3
138.2 6 28.5
146.8 6 18.0

10
8
6

146.9 6 23.4
165.6 6 13.2
163.9 6 14.2

8
5
4

.190
.071
.149

Length of tolerance to sunlight
#1 Hour

[1 Hour

Paired t test

Timepoint

DEPP QoL score
(Mean 6 SD)

No. of completed
questionnaires (n)

DEPP QoL score
(Mean 6 SD)

No. of completed
questionnaires (n)

P value

Implant 1 (Visit 2 minus 1)
Implants 1 1 2 (Visit 3 minus 1)
Implants 1 1 2 1 3 (Visit 4 minus 1)

114.6 6 23.3
128.9 6 32.7
138.9 6 0

8
5
1

155.3 6 13.9
161.1 6 13.0
155.2 6 18.3

10
8
9

\.001*
.092
.421

EPP, Erythropoietic protoporphyria; QoL, quality of life.
*Statistically significant, P \ .05. For all timepoints, P values for the comparison of mean score change within each therapeutic response
subgroup were determined by the paired t test.

In summary, afamelanotide had a positive effect
on QoL and showed a possible additive effect with
subsequent administration in a real-word setting.
Subgroups who reported treatment response variability had less robust QoL improvements. Higher or
more frequent afamelanotide doses are under investigation for treatment of other diseases, such as
vitiligo.5 As such, further prospective studies investigating individualized afamelanotide dosing strategies are needed for patients with EPP/XLP to
maximize treatment response.
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